![35-year-old American moved to Chengdu and lives on $30,000 a year: ‘[It’s] poverty in America, but in China I’m living large’](https://image.cnbcfm.com/api/v1/image/108167583-1751548516689-chinacelia1.jpg?v=1751549197&w=1920&h=1080 "35-year-old American moved to Chengdu and lives on $30,000 a year: ‘[It’s] poverty in America, but in China I’m living large’")
stock takes
Here are Jim Cramer’s rapid-fire takeaways on 6 stocks in the news Friday
Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember, our […]
Read More
January was great for stocks — here are our top 5 performers for the month
Benchmark gauges notched all-time highs as stocks charged through a busy earnings season. Source
Read More
Why we like health-care stocks in 2024 despite their spotty record in presidential election years
As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s reason to believe this year that many health-related stocks, led by Eli Lilly , could defy historical convention. The S & P 500 Health Care Sector […]
Read More
Cramer: Costco not carried out 'saturating the earth' as new China retailer lures significant crowds
Wholesale retailer Costco has a high-high quality issue on its palms, CNBC’s Jim Cramer mentioned Friday in reaction to the “purchasing frenzy” at its new China retail outlet. Bloomberg described that tens of countless numbers of people lined up outside the house of Costco’s most up-to-date store in the southern Chinese town of Shenzhen for […]
Read More
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs Jim interviewed at this week’s JPMorgan […]
Read More
Obesity and Alzheimer's drugs pack one-two punch to power Eli Lilly higher in 2024
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer […]
Read More
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled […]
Read More
Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a […]
Read More
Flying solo without Cigna will keep Humana focused on 2 big priorities in the year ahead
It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall Street Journal reported Sunday. Cigna will […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More